发给老马备查:
4 i* E" S3 E5 D9 h, ^& y/ s- ]滴水察海(69304838) 15:23:23/ A1 C$ ?2 ]; m- ~) a7 p
老马,我看到培美和S-1都提到TS低表达,而鳞多半不是低表达,是不是S-1不靠谱; M) ]& U+ t/ x& a, ]" V1 \
吉非替尼和S-1连用的依据
% `' `$ s0 B/ E+ f3 C, SGefitinib induced down-regulation of thymidylate synthase and E2F-1 in gefitinib-resistant NSCLC cells with MET amplification but not in those harboring the T790M mutation of EGFR. The combination of 5-fluorouracil and gefitinib synergistically inhibited the proliferation of cells with MET amplification, but not that of those with the T790M mutation of EGFR, in vitro.
. w! o' C! I# _. F' m是不是说因C-MET引起的耐药中,吉非替尼会引导TS低表达 q3 t2 J! Q! `3 Q" P1 k
这样是不是推理出,耐药后,可以用S-1和培美了?. x7 m9 O0 {/ |6 ~! c- N6 r
结论:" U) l; V* S7 E
如果是T790M突变引起的耐药,则2992有效,如果是C-MET扩增引起的突变,则除了184,还可以特+S1联用,而且可能可以用培美。 |